Apparatus and method for transdermal delivery of vascular endothelial growth factors

• US 20060040864A1
• Filed: 08/17/2005
• Published: 02/23/2006
• Est. Priority Date: 08/19/2004
• Status: Abandoned Application

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Maa, Yuh-Fun, Ameri, Mahmoud, Daddona, Peter, Cormier, Michel J.N., Stonebanks, Frank
• Application Number:
  US11/206,698
• Publication Number:
  US 20060040864A1
• Time in Patent Office: Days
• US Class Current: 424/448
• CPC Class Codes: A61K 38/1866 Vascular endothelial growth factor [VEGF]
• CPC Class Codes: A61K 47/26 Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61M 2037/0023 Drug applicators using microneedles
• CPC Class Codes: A61M 2037/0061 Methods for using microneedles
• CPC Class Codes: A61M 37/00 Other apparatus for introducing media into the body for reproduction or fertilisation A61B17/425; apparatus for iontophoresis or cataphoresis A61N1/30; Percutany, i.e. introducing medicines into the body by diffusion through the skin salt baths A61H33/04
• CPC Class Codes: A61M 37/0015 by using microneedles
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/08 for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or assembly) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the VEGF-based agent is contained in a biocompatible coating that is applied to the microprojection member.

Claims

1. A device for transdermally delivering a VEGF-based agent to a patient, comprising:

a microprojection member having a plurality of microprojections that are adapted to pierce the stratum corneum of the patient; and

a biocompatible coating disposed on said microprojection member, said coating being formed from a coating formulation having at least one VEGF-based agent disposed thereon.

2. The device of claim 1, wherein said coating is disposed on at least one of said plurality of microprojections.

3. The device of claim 1, wherein said coating formulation comprises an aqueous formulation.

4. The device of claim 1, wherein said coating formulation comprises a non-aqueous formulation.

5. The device of claim 1, wherein said VEGF-based agent is selected from the group consisting of isoforms of VEGF 206, VEGF 189, VEGF 183, VEGF 165, VEGF 148, VEGF 145 and VEGF 121, and salts and simple derivatives thereof.

6. The device of claim 5, wherein said VEGF 121 salt is selected from the group consisting of acetate, propionate, butyrate, pentanoate, hexanoate, heptanoate, levulinate, chloride, bromide, citrate, succinate, maleate, glycolate, gluconate, glucuronate, 3-hydroxyisobutyrate, 2-hydroxyisobutyrate, lactate, malate, pyruvate, fumarate, tartarate, tartronate, nitrate, phosphate, benzene sulfonate, methane sulfonate, sulfate and sulfonate.

7. The device of claim 1, wherein said VEGF-based agent comprises in the range of approximately 1-30 wt. % of said coating formulation.

8. The device of claim 1, wherein said VEGF-based agent comprises in the range of 1 μ

g -1000 μ

g of said biocompatible coating.

9. The device of claim 1, wherein the pH of said coating formulation is below approximately pH 5.5.

10. The device of claim 1, wherein the pH of said coating formulation is above approximately pH 7.0

11. The device of claim 1, wherein said coating formulation includes at least one low volatility counterion.

12. The device of claim 1, wherein said coating formulation includes a plurality of counterions.

13. The device of claim 9, wherein said VEGF-based agent has a positive charge at said coating formulation pH and wherein said coating formulation includes at least one acidic counterion.

14. The device of claim 12, wherein at least one of said plurality of counterions comprises a first weak acid and at least one of said plurality of counterions comprise a second non-volatile weak acid.

15. The device of claim 12, wherein at least one of said plurality of counterions comprises a second weak acid having a high volatility.

16. The device of claim 10, wherein said VEGF-based agent has a negative charge at said coating formulation pH and wherein said coating formulation includes at least a second counterion comprising a base.

17. The device of claim 12, wherein at least one of said plurality of counterions comprises a first strong base and at least one of said plurality of counterions comprises a second weak base.

18. The device of claim 12, wherein at least one of said plurality of counterions comprises a second strong base and at least one of said plurality of counterions comprises a third weak base.

19. The device of claim 11, wherein the amount of said low volatility counterion present in said coating formulation is sufficient to neutralize the charge of said VEGF-based agent.

20. The device of claim 1, wherein said VEGF-based agent comprises VEGF 121 and wherein said coating formulation includes at least one viscosity-enhancing counterion.

21. The device of claim 1, wherein said coating formulation has a viscosity in the range of approximately 3-500 centipose.

22. The device of claim 1, wherein the thickness of said biocompatible coating is less than approximately 25 microns.

23. A delivery system for transdermally delivering a VEGF-based agent to a patient, comprising:

a microprojection member having a plurality of microprojections that are adapted to pierce the stratum corneum of the patient; and

a hydrogel formulation having at least one VEGF-based agent, said hydrogel formulation being in communication with said microprojection member.

24. The delivery system of claim 23, wherein said VEGF-based agent comprises in the range of approximately 1-40 wt. % of said hydrogel formulation.

25. The delivery system of claim 23, wherein said VEGF-based agent is selected from the group consisting of isoforms of VEGF 206, VEGF 189, VEGF 183, VEGF 165, VEGF 148, VEGF 145 and VEGF 121, and salts and simple derivatives thereof.

26. The delivery system of claim 23, wherein said hydrogel formulation comprises a water-based hydrogel having a macromolecular polymeric network.

27. The delivery system of claim 23, wherein said hydrogel formulation includes at least one surfactant, selected from the group consisting of sodium lauroamphoacetate, sodium dodecyl sulfate (SDS), cetylpyridinium chloride (CPC), dodecyltrimethyl ammonium chloride (TMAC), benzalkonium, chloride, polysorbates, sorbitan derivatives, and alkoxylated alcohols.

28. A delivery system for transdermally delivering a VEGF-based agent to a patient, comprising:

a microprojection member having a plurality of microprojections that are adapted to pierce the stratum corneum of the patient;

a solid state formulation disposed proximate said microprojection member; and

a hydrogel formulation, said hydrogel formulation being in communication with said solid state formulation.

29. The delivery system of claim 28, wherein said VEGF-based agent is selected from the group consisting of isoforms of VEGF 206, VEGF 189, VEGF 183, VEGF 165, VEGF 148, VEGF 145 and VEGF 121, and salts and simple derivatives thereof.

30. The delivery system of claim 28, wherein said solid state formulation is a solid film is made by casting a liquid formulation comprising at least one VEGF-based agent, a polymeric material, a plasticizing agent, a surfactant and a volatile solvent.

31. The delivery system of claim 28, wherein said solid state formulation is formed by a process selected from the group consisting of spray drying, freeze drying, spray freeze drying and supercritical fluid extraction.

32. A method of transdermally delivering a VEGF-based agent to a patient, comprising the steps of:

providing a microprojection member having a plurality of microprojections, said microprojection member having a coating disposed thereon, said coating including at least one VEGF-based agent;

applying said microprojection member to a skin site of said patient, whereby said plurality of microprojections pierce the stratum corneum and deliver said VEGF-based agent to said patient; and

removing said microprojection member from said skin site.

33. The method of claim 32, wherein said microprojection member remains applied to said skin site for a period of time in the range of 5 sec. to 24 hrs.

34. The method of claim 32, wherein said VEGF-based agent comprises in the range of approximately 1 μ

g-1000 μ

g of said biocompatible coating.

35. A method for transdermally delivering a VEGF-based agent to a patient, comprising the steps of:

providing a microprojection assembly having a microprojection member and a gel pack, said microprojection member including a plurality of microprojections, said gel pack including a hydrogel formulation having at least one VEGF-based agent;

applying said microprojection member-gel pack assembly to a skin site of said patient, whereby a plurality of microslits are formed in the patient'"'"'s stratum-corneum, and whereby said hydrogel formulation is released from said gel pack and migrates into and through said microslits formed by said microprojections; and

removing said microprojection member-gel pack assembly from said skin site.

36. The method of claim 35, wherein said microprojection member-gel pack assembly remains applied to said skin site for a period of time in the range of 5 min. to 24 hrs.

37. The method of claim 35, wherein said microprojection member includes a biocompatible coating having at least one VEGF-based agent.

38. The method of claim 35, wherein said microprojection-gel pack assembly remains applied to said skin site for a period of time in the range of 5 sec. to 24 hours.

39. The method of claim 35, wherein VEGF-based agent is selected from the group consisting of isoforms of VEGF 206, VEGF 189, VEGF 183, VEGF 165, VEGF 148, VEGF 145 and VEGF 121, and salts and simple derivatives thereof.

40. The method of claim 35, wherein said hydrogel formulation is devoid of a VEGF-based agent.

41. A method for transdermally delivering a VEGF-based agent to a patient, comprising the steps of:

providing a microprojection assembly having a microprojection member and a gel pack, said microprojection member including a plurality of microprojections, said gel pack including a hydrogel formulation having at least one VEGF-based agent;

applying said microprojection member to a skin site of said patient, whereby a plurality of microslits are formed in the patient'"'"'s stratum-corneum;

placing said gel pack on said microprojection member, whereby said hydrogel formulation is released from said gel pack and migrates into and through said microslits formed by said microprojections; and

removing said microprojection member from said skin site.

42. The method of claim 41, wherein said gel pack includes a release liner and said method includes the step of removing said release liner prior to placing said gel pack on said microprojection member.

43. The method of claim 41, wherein said microprojection member-gel pack assembly remains applied to said skin site for a period of time in the range of 5 min. to 24 hrs.

44. The method of claim 41, wherein said microprojection member includes a biocompatible coating having at least one VEGF-based agent.

45. The method of claim 41, wherein VEGF-based agent is selected from the group consisting of isoforms of VEGF 206, VEGF 189, VEGF 183, VEGF 165, VEGF 148, VEGF 145 and VEGF 121, and salts and simple derivatives thereof.

46. The method of claim 41, wherein said VEGF-based agent comprises in the range of approximately 0.1-2 wt. % of said hydrogel formulation.

47. A method for transdermally delivering a VEGF-based agent to a patient, comprising the steps of:

providing a microprojection assembly having a microprojection member and a gel pack, said microprojection member including a plurality of microprojections, said gel pack including a hydrogel formulation having at least one VEGF-based agent;

applying said microprojection member to a skin site of said patient, whereby a plurality of microslits are formed in the patient'"'"'s stratum-corneum;

removing said microprojection member from said skin site;

placing said gel pack on said pre-treated skin site, whereby said hydrogel formulation is released from said gel pack and migrates into and through said microslits formed by said microprojections; and

removing said gel pack from said skin site.

48. The method of claim 47, wherein said gel pack remains applied to said pre-treated skin site for a period of time in the range of 5 min. to 24 hrs.

49. The method of claim 47, wherein said VEGF-based agent is selected from the group consisting of isoforms of VEGF 206, VEGF 189, VEGF 183, VEGF 165, VEGF 148, VEGF 145 and VEGF 121, and salts and simple derivatives thereof.

50. A method for transdermally delivering a VEGF-based agent to a patient, comprising the steps of:

providing a microprojection assembly having a microprojection member, a gel pack and a solid state formulation, said microprojection member including a plurality of microprojections, said gel pack including a hydrogel formulation, said solid state formulation being disposed proximate said microprojection member and including at least one VEGF-based agent;

applying said microprojection assembly to a skin site of said patient, whereby a plurality of microslits are formed in the patient'"'"'s stratum-corneum, and whereby said hydrogel formulation is released from said gel pack and releases said agent contained in said solid state formulation and said agent and hydrogel formulation migrates into through said microslits formed by said microprojections; and

removing said microprojection assembly from said skin site.

51. The method of claim 50, wherein said microprojection assembly remains applied to said skin site for a period of time in the range of 5 min. to 24 hrs.

52. The method of claim 50, wherein said VEGF-based agent is selected from the group consisting of isoforms of VEGF 206, VEGF 189, VEGF 183, VEGF 165, VEGF 148, VEGF 145 and VEGF 121, and salts and simple derivatives thereof.

53. A method for transdermally delivering a VEGF-based agent to a patient, comprising the steps of:

providing a microprojection assembly having a microprojection member and a gel pack, said microprojection member including a plurality of microprojections, said solid state formulation being disposed proximate said microprojection member and including at least one VEGF-based agent;

providing a gel pack having a hydrogel formulation;

applying said microprojection assembly to a skin site of said patient, whereby a plurality of microslits are formed in the patient'"'"'s stratum-corneum;

placing said gel pack on said microprojection assembly, whereby said hydrogel formulation is released from said gel pack and releases said agent contained in said solid state formulation and said agent and hydrogel formulation migrates into through said microslits formed by said microprojections; and

removing said microprojection assembly from said skin site.

54. The method of claim 53, wherein said gel pack includes a release liner and said method includes the step of removing said release liner prior to placing said gel pack on said microprojection assembly.

55. The method of claim 53, wherein said microprojection assembly-gel pack remains applied to said skin site for a period of time in the range of 5 min. to 24 hrs.

56. The method of claim 53, wherein said VEGF-based agent is selected from the group consisting of isoforms of VEGF 206, VEGF 189, VEGF 183, VEGF 165, VEGF 148, VEGF 145 and VEGF 121, and salts and simple derivatives thereof.